We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 12, 2020

Phase I Dose-Escalation Study of Triweekly Nab-Paclitaxel Plus S-1 for HER2− Metastatic Breast Cancer

Clinical Breast Cancer

 

Additional Info

Clinical Breast Cancer
Phase 1 Dose-Escalation Study of Triweekly Nab-Paclitaxel Combined With S-1 for HER2-Negative Metastatic Breast Cancer
Clin. Breast Cancer 2020 Jul 24;[EPub Ahead of Print], M Morimoto, H Toba, M Aoyama, M Nakagawa, H Takechi, T Yoshida, A Tangoku

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading